Day One Biopharmaceuticals (DAWN) Q4 2025 earnings review
Commercial Execution Accelerates, Nearing Operating Breakeven
Day One delivered a blowout Q4, generating $52.8 million in OJEMDA net product revenue and decisively beating prior trends. The company is rapidly approaching operating breakeven, with Q4 net loss shrinking to $21.3 million from $65.7 million a year ago. Management initiated confident 2026 revenue guidance of $225-$250 million, implying ~53% YoY growth. However, beneath the surface, a clear divergence has emerged: while revenue growth is accelerating, prescription (TRx) volume growth is decelerating, suggesting that pricing, gross-to-net improvements, or inventory stocking did the heavy lifting this quarter.
🐂 Bull Case
With $155.4 million in FY25 revenue and $441.1 million in cash, the company has proven its commercial model. Operating leverage is kicking in, effectively eliminating the need for dilutive near-term financing.
The 3-year FIREFLY-1 data showing a 42.6-month median time to next treatment solidifies OJEMDA as the unequivocal standard of care in the 2L+ setting, driving deep prescriber adoption.
🐻 Bear Case
Q4 prescriptions grew only 11% sequentially, down from 18% in Q3. If new patient starts plateau, the company will struggle to meet the higher end of its 2026 guidance without further price engineering.
Despite the Mersana acquisition, the company remains essentially a single-asset commercial story. DAY301 (Phase 1a) and Emi-Le (Phase 1) are years away from commercialization.
⚖️ Verdict: 🟢
Bullish. The commercial execution is pristine, and the balance sheet is ironclad. While the QoQ TRx volume deceleration requires monitoring, the absolute revenue generation and pipeline diversification efforts justify the premium.
Key Themes
Operating Leverage is Accelerating
Revenue growth is drastically outpacing expense growth. In Q4 2024, the company recorded a net loss of $65.7M on $29.0M of OJEMDA revenue. By Q4 2025, OJEMDA revenue surged to $52.8M while net loss compressed to $21.3M. This stable and improving cost structure proves management's disciplined approach to scaling the commercial organization.
TRx Volume Growth Contradicts Revenue Surge
A major red flag emerges when dissecting the Q4 revenue beat. Net product revenue jumped 37% sequentially ($52.8M vs $38.5M in Q3). However, prescription volumes (TRx) are decelerating, growing only 11% sequentially (1,394 vs 1,255 in Q3). This implies that Q4's revenue surge was heavily dependent on favorable gross-to-net dynamics, price increases, or channel stocking, rather than organic patient demand.
3-Year FIREFLY-1 Data Rewrites the Standard of Care
The updated 3-year data from FIREFLY-1 is a massive commercial weapon. Median time to next treatment (TTNT) reached 42.6 months, proving that OJEMDA provides durable, multi-year disease control without the rapid rebound tumor growth typically seen with off-label MEK inhibitors. This directly targets the conservative nature of pediatric oncologists by proving long-term safety and efficacy.
Mersana Acquisition Diversifies the Pipeline
Management executed a strategic acquisition of Mersana Therapeutics in January 2026, bringing Emi-Le (emiltatug ledadotin) into the fold. This B7-H4-directed ADC targets adenoid cystic carcinoma (ACC), an indication with ~1,300 annual U.S. incident patients and no approved standard of care. Phase 1 data is expected mid-2026, providing a near-term clinical catalyst.
Macro Pricing Environment and CPI-U Penalties
As noted in prior quarters, the company is vulnerable to short-term Medicaid rebate increases (CPI-U penalties) triggered by necessary price increases. In a macro environment heavily scrutinizing drug pricing, relying on price hikes to bridge the gap between TRx volume and revenue growth targets introduces regulatory and gross-to-net risk.
Frontline Expansion Relies on High-Risk Crossover Design
The Phase 3 FIREFLY-2 trial is Day One's ticket to the lucrative frontline pLGG market, effectively doubling the TAM. However, the trial utilizes a crossover design where patients progressing on the standard-of-care arm can receive OJEMDA. If the crossover muddies the primary endpoint data (ORR per RAPNO), it could complicate the 2028 potential FDA approval.
Other KPIs
Stable. The company consumed only ~$10M in cash during Q4, down from the massive burn rates of 2024. This essentially guarantees financial independence and funds operations well past the FIREFLY-2 data readout.
Decelerating. Down from $227.7 million in FY24. The drop is primarily attributed to the absence of massive upfront licensing payments (like the MabCare deal in 2024), reflecting a normalization of run-rate R&D as FIREFLY-2 enrollment matures.
Stable. SG&A ticked up slightly from $115.5 million in FY24, an impressive feat of cost control considering 2025 was the first full year of commercial launch activities for OJEMDA.
Guidance
Decelerating growth rate, but strong absolute dollars. The $237.5M midpoint implies a 53% YoY growth rate compared to FY25's $155.4M. This suggests management expects steady, durable patient persistence rather than hockey-stick new patient starts.
Stable. Management reaffirmed this timeline, maintaining the trajectory for topline data in mid-2027 to support a potential 2028 frontline approval.
Key Questions
TRx vs Revenue Disconnect
Q4 revenue grew 37% sequentially, while prescriptions grew only 11%. How much of the Q4 revenue beat was driven by one-time channel stocking or gross-to-net adjustments versus true underlying patient demand?
Emi-Le Integration Costs
With the Mersana acquisition closing in January 2026, how should we model the incremental R&D and SG&A burn associated with integrating and advancing the Emi-Le program this year?
Frontline Cannibalization
As FIREFLY-2 approaches full enrollment in H1 2026, are you seeing any instances of physicians warehousing newly diagnosed patients or utilizing off-label OJEMDA in the frontline setting ahead of formal approval?